Simvastatin therapy decreases MMP-9 levels in obese women

Journal of Clinical Pharmacology

Volumn 53, Issue 10, 2013, Pages 1072-1077

  Andrade, Vanessa Leite ^a   Do Valle, Izabella Batistelli ^a   Sandrim, Valeria Cristina ^a  

^a Santa Casa de Belo Horizonte (SCBH)   (Brazil)

Author keywords

Cardiovascular risk; Mmp 9; Obesity; Simvastatin; TIMP 1

Indexed keywords

GELATINASE A; GELATINASE B; PLACEBO; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADIPOSE TISSUE; ADULT; ARTICLE; CARDIOVASCULAR RISK; CASTELLI INDEX; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; OBESITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE BLIND PROCEDURE;

CARDIOVASCULAR RISK; MMP-9; OBESITY; SIMVASTATIN; TIMP-1;

ADULT; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OBESITY; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84885110832     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.146     Document Type: Article

References (35)

1. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinology and Metabolism Clinics of North America. 2008;37(3):753-768, x-xi.
2. Bouloumié A, Sengenès C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes. 2001;50(9):2080-2086. (Pubitemid 33643675)
3. Andrade VL, Petruceli E, Belo VA, et al. Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. Clinical Biochemistry. 2012;45(6):412-415.
4. Miksztowicz V, Siseles N, Fernandez Machulsky N, Schreier L, Berg G. Increase in MMP-2 activity in overweight and obese women is associated with menopausal status. Climacteric: The Journal of the International Menopause Society. 2012;15(6):602-606.
5. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M. Plasma levels of matrix metalloproteinase-9 are independently associated with psychosocial factors in a middle-aged normal population. Psychosomatic Medicine. 2009;71(3):292-300.
6. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke. 2000;31(1):40-47. (Pubitemid 30035750)
7. Heo SH, Cho C-H, Kim HO, et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. Journal of Clinical Neurology (Seoul, Korea). 2011;7(2):69-76.
8. Koh KK, Ahn JY, Jin DK, et al. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. International Journal of Cardiology. 2004;97(2): 239-244. (Pubitemid 39286842)
9. Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase- 9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(2):372.
10. Derosa G, Cicero AFG, Scalise F, et al. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium: Journal of Endothelial Cell Research. 2007;14(1): 45-451.
11. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207-213. (Pubitemid 30044262)
12. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001; 103(7):993-999. (Pubitemid 32183806)
13. Son JW, Koh KK, Ahn JY, et al. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. International Journal of Cardiology. 2003;88(1): 77-82. (Pubitemid 36351413)
14. Kurzepa J, Szczepanska-Szerej A, Stryjecka-Zimmer M, Malecka- Massalska T, Stelmasiak Z. Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Folia Biologica. 2006;52(6):181-183. (Pubitemid 46020160)
15. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. Journal of the American College of Cardiology. 2007; 49(3):290-297. (Pubitemid 46110954)
16. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(5):769-775. (Pubitemid 36566165)
17. Koh KK. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22(9):19e-23e.
18. Baumgartner RN, Heymsfield SB, Roche AF. Human body composition and the epidemiology of chronic disease. Obesity Research. 1995;3(1):73-95.
19. Bioelectrical impedance analysis in body composition measurement: National Institutes of Health technology assessment conference statement. The American Journal of Clinical Nutrition. 1996;64(3 Suppl):524S-532S.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry. 1972;18(6):499-502.
21. Borona E, Targher G, Alberiche M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000;23(1):57-63.
22. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983;67(4):730-734. (Pubitemid 13161449)
23. Kannel WB. The Framingham study: ITS 50-year legacy and future promise. Journal of Atherosclerosis and Thrombosis. 2000;6(2): 60-66.
24. Buege JA, Aust. SD. Microsomal lipid peroxidation. Methods in Enzymology 1978;52:302-310.
25. Palei ACT, Sandrim VC, Duarte G, Cavalli RC, Gerlach RF, Tanus- Santos JE. Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2010;411(11-12):874-877.
26. Andrade VL, Fernandes KS, Bosco AA, Tanus-Santos JE, Sandrim VC. Functional polymorphism located in MMP-9 gene promoter is strongly associated with obesity. DNA and Cell Biology. 2012; 31(6):1054-1057.
27. Turner NA, Aley PK, Hall KT, Warburton P, Galloway S, Midgley L. Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via bothMMP-9 dependent and -independent mechanisms. Journal of Molecular and Cellular Cardiology. 2007;43(2):168-176. (Pubitemid 47069380)
28. Rahat MA, Marom B, Bitterman H, Weiss-Cerem L, Kinarty A, Lahat N. Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association. Journal of Leukocyte Biology. 2006;79(4): 706-718. (Pubitemid 44835603)
29. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovascular Research. 2004;64(3):507-515. (Pubitemid 39505429)
30. Evans J, Powell JT, Schwalbe E, Loftus IM, Thompson MM. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. European Journal of Vascular and Endovascular Surgery: The Official Journal of the European Society for Vascular Surgery. 2007;34(3):302-303. (Pubitemid 47194427)
31. Wu Y-W. Kao H-L, Huang C-L, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. European Journal of Nuclear Medicine and Molecular Imaging. 2012;39(3):399-407.
32. Izidoro-Toledo TC, Guimaraes DA, Belo VA, Gerlach RF, Tanus- Santos JE. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn-Schmiedeberg's Archives of Pharmacology. 2011;383(6):547-554.
33. Goldberg GI, Strongin A, Collier IE, Genrich LT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. The Journal of Biological Chemistry. 1992;267(7): 4583-4591.
34. Kostapanos MS, Elisaf MS. JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. World Journal of Cardiology. 2011;3(7):207-214.
35. Olkinuora JT, Viikari J, Vanhanen H, Makkonen N, Kalliomäki T. Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study). Scandinavian Cardiovascular Journal: SCJ. 2006;40(3):160-166. (Pubitemid 44335994)